The science behind BPL1

THE
SCIENCE
BEHIND
BPL1
THE SCIENCE BEHIND BPL1

BPL1 is ADM’s probiotic strain with significant results in visceral fat and abdominal circumference reduction. Its efficacy has been verified, both with living strains and with HT, thereby providing for application in solid and in liquid formulas. This all being said, BPL1 is already a benchmark probiotic for important nutrition brands. However, if you will allow, we can also be the seal of nutritional quality that your clients are looking for.

Key aspects of the trial 3-month treatment 1010 cfu/day Effects seen in both alive and heat-killed BPL1 groups
Key aspects of the trial 3-month treatment 1010 cfu/day Effects seen in both alive and heat-killed BPL1 groups

Human clinical trial

Our latest assessment of the effects of BPL1 has been a clinical trial performed with abdominally obese subjects. Results of this research have been published in the top journal on obesity and metabolic disorders, the International Journal of Obesity from Nature Publishing Group (IF = 5.16).

The clinical trial involved 135 subjects (>18 years old, mean age: 42), 126 of which finished the complete treatment after three months. Patients had either placebo (n = 40), alive BPL1 (n = 42) or heat-killed BPL1 (n = 44). The dosage of probiotic was 1010 cfu/day (or cfu equivalent in the case of the heat-killed BPL1). No differences in baseline characteristics were observed among intervention groups.

Both BPL1 treatments (alive and heat-killed) reduced the visceral fat area (VFA), body mass index (BMI), waist circumference (WC), waist circumference to height ratio (WHtR), and conicity index (CI). Of particular interest is the reduction of visceral fat, which has been linked to a higher risk of stroke and other cardiovascular diseases.

The microbiome of subjects under BPL1 consumption also changed after treatment to a higher prevalence of Bifidobacterium and Akkermansia. These results support the effect of the strain on the modulation of the microbiome and energy metabolism.

Placebo (n = 40)
BPL1 (n = 42)
ht-BPL1 (n = 44)
Treatment/day
300 mg of maltodextrin
1010 cfu BPL1 formulated in maltodextrin
-heat-treated BPL1 (equivalent 1010 cfu) formulated in maltodextrin
Treatment/day
Placebo (n = 40)
300 mg of maltodextrin
BPL1 (n = 42)
1010 cfu BPL1 formulated in maltodextrin
ht-BPL1 (n = 44)
-heat-treated BPL1 (equivalent 1010 cfu) formulated in maltodextrin
Main results
Significant reduction of waist circumference (1-2cm)
Significant reduction of abdominal visceral fat (3-7cm²)
Previous
Next
Main results
Significant reduction of waist circumference (1-2cm)
Significant reduction of abdominal visceral fat (3-7cm²)
Previous
Next

Key findings

Isolated from healthy babies found using an in vivo model for fat reduction works when heat-treated Strong anti-oxidant effect.

Discovery and safety

BPL1 was isolated from the faeces of a healthy breast-fed under three months old baby. It is classified as a Bifidobacterium lactis subsp. animalis and was deposited in the Spanish type culture collection under the code CECT 8145. Their safety has been evaluated in…

Terms of genome sequencing – no virulent genes were found –, antibiotic resistance – MIC values under EFSA breaking points – , assays to corroborate lack of production undesired metabolites -biogenic amines-, production of D- and L- lactate and bile salt hydrolase activity. Safety was also assessed by acute ingestion assays in healthy and immunosuppressed murine models –no morbidity neither weight loss, histological issues or translocation. BPL1 is in the QPS list and has self-affirmed GRAS status in the U.S .

Our screening technology behind the identification of BPL1 was founded in the use of Caenorhabditis elegans as an in vivo model for fat reduction. Accumulated fats were quantified by fluorescence after growing the nematode in the presence of each of the 23 Lactobacillus strains and 15 Bifidobacterium. The results show the highest amount of body-fat reduction in the case of BPL1, outperforming well-established probiotic strains that were also included in the study. The effect of the strain was maintained after a heat treatment (121 °C, 30 min)

The model was also used to assess the antioxidant effect of the strain, which was remarkable when compared to control conditions. The survival assay was based on an acute oxidative stress caused by the addition of H2O2. Worms fed with BPL1 showed much more resistance towards the shock (64% survival vs 34% of control).

The effect of the strain on the nematode was further evaluated by transcriptomic and metabolic assays, which led to the conclusion that the main metabolic pathways affected were energy and lipid metabolism. Feeding behavior through tryptophan metabolism, muscle contraction and a oxidative stress and inflammation response were also identified as the main changes induced by the intake of the probiotic that are related to obesity.

Previous
Next
Previous
Next

Key findings

Reduced adiposity, body weight improved cardiovascular risk

Assays in other animal models

The effect of BPL1 was also tested in murine models before the human clinical trail. These assays were useful to donfirm the weight reduction capabilities of the strain as well as to further evaluate the functionality of heat-killed BPL1.

Previous
Next
Previous
Next

The strength of BPL1 in other probiotic combinations

The strength of BPL1 has also been demonstrated when combined with other strains for a synergistic effect. Biopolis has developed specific probiotic consortia to alleviate symptoms occurring in skin disorders, such as atopic dermatitis and psoriasis. The powerful antioxidant effect of BPL1 is key to obtain a holistic bacterial product that is able to treat different aspects of the aforementioned conditions.

Atopic dermatitis

In the case of the atopic dermatitis BPL1 containing probiotic product, a drastic reduction on the consumption of corticosteroids after 6 weeks of treatment was shown in a randomized, parallel, double-blind, placebo controlled trial with 50 children aged from 4 to 17 years with moderate AD. Results of the trial, also showed a 90% clearance of the symptoms in the group taking the probiotic BPL1 containing product, compared with a 20% in the placebo group after 12-weeks. Results from this study were published in JAMA Dermatology.

Psoriasis

Similar results where obtained in the clinical trial of Biopolis probiotic product containing BPL1 specific for psoriasis. The randomized, parallel, double-blind, placebo controlled trial with 90 psoriatic patients showed a significant increase in the number of patients who have achieved a 75% or more reduction in their PASI score from baseline – the main psoriasis severity index. 

Both cases on skin health show the potential of BPL1 as a part of a dedicated probiotic consortia, due to its great antioxidant and anti-inflammatory properties.